Tags

Type your tag names separated by a space and hit enter

Changes in central corneal thickness over time: the ocular hypertension treatment study.
Ophthalmology 2008; 115(9):1550-6, 1556.e1O

Abstract

OBJECTIVE

To describe how much change, if any, occurs between central corneal thickness (CCT) measurements performed an average of 3.8 years apart in participants in the Ocular Hypertension Treatment Study (OHTS) and to identify clinical and demographic factors that are associated with changes in CCT, including baseline intraocular pressure, duration and class of ocular hypotensive medication, medical history, and systemic medication.

DESIGN

Secondary analysis of data from a randomized clinical trial.

PARTICIPANTS

Ocular Hypertension Treatment Study participants. Participants who had undergone incisional intraocular or keratorefractive surgery between CCT measurements were excluded.

TESTING

The first CCT measurements were performed starting in 1999, and the second measurements were performed starting in 2002. Measurements were performed by OHTS certified technicians using an ultrasonic pachymeter under a standardized protocol.

MAIN OUTCOME MEASURE

Central corneal thickness measurement (micrometers).

RESULTS

First and second CCT measurements were available from 73% (1191) of the 1636 OHTS participants randomized. Central corneal thickness decreased a mean rate of -0.74+/-3.5 microm/year between the first and second CCT measurements. The mean medication exposure between first and second CCT measurements in participants originally randomized to observation (n = 595) was 1.1+/-1.6 years, versus 5.0+/-2.7 years in participants originally randomized to medication (n = 596). Central corneal thickness decreased by a mean of 1.0+/-3.4 microm/year among participants originally randomized to observation, compared with 0.5+/-3.5 microm/year among participants originally randomized to medication (P<0.0001). Subgroup analyses suggest that participants treated only with topical prostaglandin analogues (PGAs) between the two CCT measurements had a greater rate of decrease per year than participants treated only with topical beta-blockers.

CONCLUSIONS

The rate of CCT decrease over 3.8 years is comparable to the cross-sectional age differences reported in the OHTS at the first measurement (0.6 microm/year) and comparable to other cross-sectional studies. Use of topical PGAs may be associated with a slightly higher rate of thinning. The modest age- and drug-related rates of thinning observed are unlikely to influence tonometry or clinical decision-making substantially in most clinical situations.

Authors+Show Affiliations

Department of Ophthalmology and Vision Science, University of California, Sacramento, California, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

18378313

Citation

Brandt, James D., et al. "Changes in Central Corneal Thickness Over Time: the Ocular Hypertension Treatment Study." Ophthalmology, vol. 115, no. 9, 2008, pp. 1550-6, 1556.e1.
Brandt JD, Gordon MO, Beiser JA, et al. Changes in central corneal thickness over time: the ocular hypertension treatment study. Ophthalmology. 2008;115(9):1550-6, 1556.e1.
Brandt, J. D., Gordon, M. O., Beiser, J. A., Lin, S. C., Alexander, M. Y., & Kass, M. A. (2008). Changes in central corneal thickness over time: the ocular hypertension treatment study. Ophthalmology, 115(9), pp. 1550-6, 1556.e1. doi:10.1016/j.ophtha.2008.02.001.
Brandt JD, et al. Changes in Central Corneal Thickness Over Time: the Ocular Hypertension Treatment Study. Ophthalmology. 2008;115(9):1550-6, 1556.e1. PubMed PMID: 18378313.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Changes in central corneal thickness over time: the ocular hypertension treatment study. AU - Brandt,James D, AU - Gordon,Mae O, AU - Beiser,Julia A, AU - Lin,Shan C, AU - Alexander,Monica Y, AU - Kass,Michael A, AU - ,, Y1 - 2008/04/18/ PY - 2007/10/24/received PY - 2008/02/04/revised PY - 2008/02/04/accepted PY - 2008/4/2/pubmed PY - 2008/9/13/medline PY - 2008/4/2/entrez SP - 1550-6, 1556.e1 JF - Ophthalmology JO - Ophthalmology VL - 115 IS - 9 N2 - OBJECTIVE: To describe how much change, if any, occurs between central corneal thickness (CCT) measurements performed an average of 3.8 years apart in participants in the Ocular Hypertension Treatment Study (OHTS) and to identify clinical and demographic factors that are associated with changes in CCT, including baseline intraocular pressure, duration and class of ocular hypotensive medication, medical history, and systemic medication. DESIGN: Secondary analysis of data from a randomized clinical trial. PARTICIPANTS: Ocular Hypertension Treatment Study participants. Participants who had undergone incisional intraocular or keratorefractive surgery between CCT measurements were excluded. TESTING: The first CCT measurements were performed starting in 1999, and the second measurements were performed starting in 2002. Measurements were performed by OHTS certified technicians using an ultrasonic pachymeter under a standardized protocol. MAIN OUTCOME MEASURE: Central corneal thickness measurement (micrometers). RESULTS: First and second CCT measurements were available from 73% (1191) of the 1636 OHTS participants randomized. Central corneal thickness decreased a mean rate of -0.74+/-3.5 microm/year between the first and second CCT measurements. The mean medication exposure between first and second CCT measurements in participants originally randomized to observation (n = 595) was 1.1+/-1.6 years, versus 5.0+/-2.7 years in participants originally randomized to medication (n = 596). Central corneal thickness decreased by a mean of 1.0+/-3.4 microm/year among participants originally randomized to observation, compared with 0.5+/-3.5 microm/year among participants originally randomized to medication (P<0.0001). Subgroup analyses suggest that participants treated only with topical prostaglandin analogues (PGAs) between the two CCT measurements had a greater rate of decrease per year than participants treated only with topical beta-blockers. CONCLUSIONS: The rate of CCT decrease over 3.8 years is comparable to the cross-sectional age differences reported in the OHTS at the first measurement (0.6 microm/year) and comparable to other cross-sectional studies. Use of topical PGAs may be associated with a slightly higher rate of thinning. The modest age- and drug-related rates of thinning observed are unlikely to influence tonometry or clinical decision-making substantially in most clinical situations. SN - 1549-4713 UR - https://www.unboundmedicine.com/medline/citation/18378313/Changes_in_central_corneal_thickness_over_time:_the_ocular_hypertension_treatment_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(08)00104-8 DB - PRIME DP - Unbound Medicine ER -